Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Condition:   Mesothelioma Interventions:   Drug: Nivolumab Injection;   Drug: Ipilimumab Injection Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials